Podcasts · Science

Talking Points

TCTMD

213 episodes

A selection of the best interviews conducted by physician leaders and recorded at cardiology conferences around the globe. 06f763f0-76e5-11f0-bb7c-8557ae1d8a8b

Episodes page 2 of 5

  1. The ECLS-SHOCK Trial

    · 10 min

    Holger Thiele and C. Michael Gibson discuss the impact of VA-ECMO on patients with acute MI and advanced cardiogenic shock.

  2. The STOPDAPT-3 Trial

    · 9:03

    Masahiro Natsuaki and C. Michael Gibson discuss this latest randomized comparison of prasugrel monotherapy and DAPT with aspirin for patients undergoing PCI.

  3. The ILUMIEN IV Trial

    · 12 min

    Ziad Ali and C. Michael Gibson take a deeper dive into this comparison of OCT- and angiography-guided PCI.

  4. OCT vs IVUS vs Angiography: A Meta-analysis

    · 8:05

    Gregg Stone and C. Michael Gibson discuss an updated meta-analysis addressing intravascular imaging in DES implantation.

  5. The ATTRibute-CM Trial

    · 6:52

    Julian Gillmore and C. Michael Gibson discuss the efficacy of acoramidis for patients with transthyretin amyloid cardiomyopathy.

  6. The ADVENT Trial

    · 10 min

    Vivek Reddy and C. Michael Gibson compare pulsed field ablation versus thermal ablation for patients with paroxysmal atrial fibrillation.

  7. The ARAMIS Trial

    · 7:48

    Mathieu Kerneis and C. Michael Gibson compare outcomes of patients treated with anakinra, a new therapy for acute myocarditis, or placebo.

  8. The NITRATE-CIN Trial

    · 9:50

    Dan Jones and C. Michael Gibson discuss whether inorganic nitrate reduces contrast-induced nephropathy after angiography in ACS patients.

  9. The DICTATE-AHF Trial

    · 9:33

    Zachary Cox and C. Michael Gibson discuss whether early dapagliflozin initiation is safe and effective for patients with acute heart failure.

  10. The RIGHT Trial

    · 8:14

    Shaoping Nie, Gilles Montalescot, and C. Michael Gibson discuss prolonged anticoagulation after primary PCI for patients with MI.

  11. Four-Year Results: The EVOLUT Low Risk Trial

    · 5:51

    Michael J. Reardon and C. Michael Gibson discuss the trial's 4-year results in low-surgical-risk patients with severe aortic stenosis randomized to self-expanding TAVI or SAVR.

  12. The AGENT IDE Trial

    · 10 min

    Robert W. Yeh and C. Michael Gibson discuss the primary outcomes of this eagerly awaited trial comparing the AGENT paclitaxel-coated balloon with conventional balloon angioplasty for in-stent restenosis.

  13. The TRISCEND II Trial

    · 6:50

    Susheel K. Kodali and C. Michael Gibson discuss transcatheter tricuspid valve replacement in patients with severe tricuspid regurgitation.

  14. The VIVA Trial

    · 5:00

    Josep Rodés-Cabau and C. Michael Gibson discuss the benefits of TAVI versus SAVR in patients with severe aortic stenosis and small aortic annuli.

  15. The SELECT Trial

    · 13 min

    A. Michael Lincoff and C. Michael Gibson discuss the cardiovascular impact of semaglutide in patients with overweight or obesity but without diabetes.

  16. The MINT Trial

    · 11 min

    Jeffrey Carson and Serge Korjian discuss restrictive versus liberal blood transfusion in patients with MI and anemia.

  17. The ORBITA-2 Trial

    · 21 min

    Christopher Rajkumar, Rasha Al-Lamee, and C. Michael Gibson discuss this randomized trial of PCI versus a placebo procedure for stable angina.

  18. The ARIE-HM3 Trial

    · 15 min

    Mandeep Mehra and C. Michael Gibson discuss whether or not aspirin is needed for patients with left ventricular assist devices in advanced heart failure.

  19. The AZALEA - TIMI Trial

    · 13 min

    Christian T. Ruff and C. Michael Gibson discuss the primary results of a randomized trial testing the efficacy of abelacimab versus rivaroxaban for stroke prevention in atrial fibrillation.

  20. The heart-1 Trial of VERVE-101

    · 5:16

    Andrew Bellinger, Sek Kathiresan, and C. Michael Gibson talk about the phase 1b trial of what investigators hope may be a one-time genetic fix for hyperlipidemia.

  21. Lepodisiran Phase I Trial

    · 5:22

    Steven Nissen and C. Michael Gibson discuss the efficacy and safety of lepodisiran, an extended duration short-interfering RNA meant to reduce lipoprotein (a).

  22. CLEAR Outcomes Subanalysis

    · 10 min

    Paul Ridker and C. Michael Gibson discuss whether residual inflammatory risk or residual cholesterol risk is a more effective predictor of CV events among patients treated with statins.

  23. The AXIOMATIC - SSP Trial

    · 8:35

    Mike Sharma and C. Michael Gibson discuss managing acute thromboembolic events in secondary stroke using antithrombotic treatment with factor XIa inhibition.

  24. The EBRAVE - AF Trial

    · 9:01

    Axel Bauer and C. Michael Gibson talk about whether smartphone-based screening can effectively detect atrial fibrillation in elderly, at-risk patients.

  25. The INVICTUS Trial

    · 17 min

    Ganesan Karthikeyan and C. Michael Gibson compare the efficacy of rivaroxaban versus vitamin K agonists for patients with rheumatic heart disease associated atrial fibrillation

  26. The FRAME-AMI Trial

    · 9:07

    Joo-Yong Hahn and C. Michael Gibson compare FFR with angiography-guided PCI for patients with acute myocardial infarction and multivessel disease.

  27. MASTER DAPT: Long-Term Results

    · 5:58

    Marco Valgimigli and C. Michael Gibson discuss the long-term follow-up results from MASTER DAPT, which compared the outcomes of high bleeding risk patients randomized to either abbreviated or standard antiplatelet…

  28. Episode 180: The PANTHER Trial

    · 8:19

    Marco Valgimigli and C. Michael Gibson discuss the PANTHER trial, which compared P2Y12 inhibitor monotherapy with aspririn monotherapy in patients with coronary artery disease.

  29. Radial vs. Femoral Access for PCI: Meta-Analysis

    · 9:44

    Giuseppe Gargiulo and C. Michael Gibson discuss whether the choice of radial or femoral artery access impacts the risk of mortality and major bleeding for patients undergoing coronary procedures.

  30. Episode 181: ACT Outpatient and Inpatient Trials

    · 5:39

    Sanjit Jolly and C. Michael Gibson discuss if colchicine and rivaroxaban plus aspirin can slow disease progression in patients hospitalized with COVID-19.

  31. Episode 180: The VALOR-HCM Trial

    · 9:35

    Milind Desai and C. Michael Gibson compare the results of mavacamten for severe obstructive hypertropic cardiomyopathy with the typical treatments of surgical septal myectomy or alcohol ablation.

  32. Episode 179: The SODIUM-HF Study

    · 11 min

    Justin Ezekowitz and C. Michael Gibson look at a sodium-reducing dietary intervention and its effects on patients with HF.

  33. Episode 178: The COMPLETE Trial

    · 7:44

    Shamir Mehta and C. Michael Gibson discuss how complete revascularization affects angina-related quality of life in patients with STEMI.

  34. Episode 177: The EDIT-CMD Trial

    · 11 min

    Tijn Jansen, Suzette Elias-Smale, and C. Michael Gibson discuss whether diltiazem improves coronary vasomotor dysfunction in patients with angina and nonobstructive coronary artery disease.

  35. Episode 176: The IVVE Trial

    · 7:21

    Mark Loeb and C. Michael Gibson discuss whether the influenza vaccine can reduce adverse vascular events among patients with HF.

  36. Episode 175: The METEORIC-HF Trial

    · 8:53

    Gregory Lewis and C. Michael Gibson discuss how omecamtiv mecarbil affects exercise tolerance in patients with chronic HFrEF.

  37. Episode 174: The DIAMOND Trial

    · 7:50

    Javed Butler and C. Michael Gibson discuss using patiromer to manage hyperkalemia in patients with HFrEF who are taking RAAS inhibitors.

  38. Episode 173: MAVA-LTE: The EXPLORER-LTE Cohort

    · 8:13

    Florian Rader and C. Michael Gibson look at cumulative outcomes for patients with obstructive hypertrophic cardiomyopathy treated with mavacamten.

  39. Episode 172:The PACIFIC-AF Study

    · 7:54

    Manesh Patel and C. Michael Gibson discuss the results of a phase II trial comparing the safety profiles of asundexian versus apixaban in patients with atrial fibrillation.

  40. Episode 171: The PROTECT Trial

    · 7:19

    Daniel Sessler and C. Michael Gibson compare myocardial injury rates following mild hypothermia versus aggressive warming during noncardiac surgery.

  41. Episode 170: The ADAPT-TAVR Trial

    · 15 min

    Duk-Woo Park and C. Michael Gibson discuss edoxaban vs dual antiplatelet therapy for valve thrombosis and cerebral thromboembolism after TAVI.

  42. Episode 169: The FLAVOUR Trial

    · 17 min

    Bon-Kwon Koo and C. Michael Gibson compare the efficacy of FFR-guided and IV ultrasound-guided PCI for coronary artery stenosis.

  43. Episode 168: The GIPS-IV Study

    · 8:09

    Marie-Sophie de Koning and C. Michael Gibson discuss whether the use of sodium thiosulfate after STEMI helps preserve cardiac function.

  44. Episode 167: The Spyral HTN-ON MED Pilot Study

    · 5:00

    Felix Mahfoud and C. Michael Gibson examine the efficacy of renal denervation for long-term BP reduction in patients taking antihypertensive medication.

  45. Episode 166: Chronic Kidney Disease In CANTOS

    · 7:23

    Paul Ridker and C. Michael Gibson discuss a secondary analysis from CANTOS looking at residual inflammatory and cholesterol risks based on chronic kidney disease status.

  46. Episode 165: The STAR-T/D Trial

    · 4:21

    Michael Mack and C. Michael Gibson discuss a novel method for extracting antithrombotics from the blood during CABG.

  47. Episode 164: The LOOP Study for AF Screening

    · 17 min

    C. Michael Gibson and Jesper Hastrup Svendsen discuss the use of implantable loop recorders to prevent stroke in AF.

  48. Episode 163: The ENVISAGE-TAVI AF Trial

    · 7:18

    C. Michael Gibson and George Dangas discuss edoxaban vs vitamin K antagonists after TAVI in patients with atrial fibrillation.

  49. Episode 162: The FIGARO-DKD Trial

    · 7:30

    Episode 162: The FIGARO-DKD Trial by TCTMD

  50. Episode 161: AMULET-IDE: One-Year Outcomes

    · 6:45

    C. Michael Gibson and Dhanunjaya Lakkireddy discuss device success and thrombus risk in Amulet versus Watchman for LAA closure.

Shows are listed from Apple Podcasts' charts and directory, and Podcast Index where it is used. Every show and episode belongs to its publisher and plays from the publisher's own feed; this site hosts none of them. Explicit shows are for adult profiles only, and children’s profiles hear only children’s shows. More about this list.